ReviewFoods (Basel, Switzerland)2026
Konjac Glucomannan: From Molecular Architecture to Translational Applications-A Critical Review of Structure-Function Relationships, Emerging Biomedical Frontiers, and Industrial Challenges.
Review in Foods (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Konjac glucomannan (KGM) is a plant-derived polysaccharide with a long history of food use and a rapidly expanding portfolio of biomedical applications. Yet despite decades of research, translation of KGM-based materials from laboratory proof-of-concept to clinical and commercial products remains slow, hampered by unresolved structural controversies, batch-to-batch variability, and a lack of quantitative design rules. This review provides a critical, mechanism-focused analysis of KGM across its molecular architecture, extraction and modification, and translational applications, moving beyond cataloguing uses to evaluate conflicting findings in the literature. We examine how hierarchical structural features-molecular weight, acetylation pattern, and chain topology-govern solution behavior, gelation, and biological performance, and compare KGM with competing biopolymers to define its unique advantages and inherent limitations. Current progress in colon-targeted delivery, wound healing, microbiome modulation, and metabolic health is synthesized, and persistent barriers to translation are evaluated, including the absence of quantitative structure-activity models, limited human pharmacokinetic data, and incomplete toxicological characterization of modified derivatives. We also address longstanding debates over branching frequency, acetylation distribution, and dose-response relationships that have generated inconsistent results across studies. Finally, we outline a research agenda integrating computational polymer design, multi-omics mechanistic studies, and precision nutrition to support development of next-generation KGM biomaterials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.